{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T14:56:15Z","timestamp":1762095375601,"version":"build-2065373602"},"reference-count":36,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,8]],"date-time":"2025-06-08T00:00:00Z","timestamp":1749340800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical and Biophysical Research Communications"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1016\/j.bbrc.2025.152172","type":"journal-article","created":{"date-parts":[[2025,6,7]],"date-time":"2025-06-07T02:29:42Z","timestamp":1749263382000},"page":"152172","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Immunosuppressive MAP3K11 as an independent risk factor for progression-free survival promotes prostate cancer metastasis by regulating epithelial-mesenchymal transition"],"prefix":"10.1016","volume":"775","author":[{"given":"Zhiming","family":"Zhang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guohao","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hualing","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weiming","family":"Dong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yiqiao","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xuancheng","family":"Feng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiao","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kaiyue","family":"Tang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maozhi","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhengming","family":"Su","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbrc.2025.152172_bib1","first-page":"209","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.bbrc.2025.152172_bib2","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2022.215927","article-title":"Prostate cancer treatment - china's perspective","volume":"550","author":"Liu","year":"2022","journal-title":"Cancer Lett."},{"key":"10.1016\/j.bbrc.2025.152172_bib3","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.puhe.2019.04.016","article-title":"Trends and age-period-cohort effect on incidence and mortality of prostate cancer from 1990 to 2017 in China","volume":"172","author":"Liu","year":"2019","journal-title":"Public Health"},{"key":"10.1016\/j.bbrc.2025.152172_bib4","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.23115","article-title":"Relative burden of cancer and noncancer mortality among long-term survivors of breast, prostate, and colorectal cancer in the US","volume":"6","author":"Kc","year":"2023","journal-title":"JAMA Netw. Open"},{"key":"10.1016\/j.bbrc.2025.152172_bib5","first-page":"12","article-title":"Cancer statistics","volume":"74","author":"Siegel","year":"2024","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.bbrc.2025.152172_bib6","doi-asserted-by":"crossref","first-page":"1882","DOI":"10.1001\/jama.2017.4011","article-title":"Screening for thyroid cancer: US preventive services task force recommendation statement","volume":"317","author":"Force","year":"2017","journal-title":"JAMA"},{"key":"10.1016\/j.bbrc.2025.152172_bib7","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1093\/jnci\/djad193","article-title":"Prostate cancer screening in African American men: a review of the evidence","volume":"116","author":"Kensler","year":"2024","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.bbrc.2025.152172_bib8","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1158\/1055-9965.EPI-22-1038","article-title":"Estimating the number of men living with metastatic prostate cancer in the United States","volume":"32","author":"Devasia","year":"2023","journal-title":"Cancer Epidemiol. Biomarkers Prev."},{"key":"10.1016\/j.bbrc.2025.152172_bib9","doi-asserted-by":"crossref","first-page":"1886","DOI":"10.1016\/S0140-6736(21)01790-6","article-title":"The addition of androgen deprivation therapy and pelvic lymph node treatment to prostate bed salvage radiotherapy (NRG Oncology\/RTOG 0534 SPPORT): an international, multicentre, randomised phase 3 trial","volume":"399","author":"Pollack","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.bbrc.2025.152172_bib10","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.semcancer.2021.05.010","article-title":"RAF-MEK-ERK pathway in cancer evolution and treatment","volume":"85","author":"Ullah","year":"2022","journal-title":"Semin. Cancer Biol."},{"key":"10.1016\/j.bbrc.2025.152172_bib11","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.ccell.2018.12.002","article-title":"Gain fat-lose metastasis: converting invasive breast cancer cells into adipocytes inhibits cancer metastasis","volume":"35","author":"Ishay-Ronen","year":"2019","journal-title":"Cancer Cell"},{"key":"10.1016\/j.bbrc.2025.152172_bib12","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1038\/s41392-023-01705-z","article-title":"Targeting the RAS\/RAF\/MAPK pathway for cancer therapy: from mechanism to clinical studies","volume":"8","author":"Bahar","year":"2023","journal-title":"Signal Transduct. Targeted Ther."},{"key":"10.1016\/j.bbrc.2025.152172_bib13","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1056\/NEJMoa1904059","article-title":"Five-year outcomes with dabrafenib plus trametinib in metastatic melanoma","volume":"381","author":"Robert","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bbrc.2025.152172_bib14","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1158\/2159-8290.CD-17-1226","article-title":"Combined BRAF, EGFR, and MEK inhibition in patients with BRAF(V600E)-Mutant colorectal cancer","volume":"8","author":"Corcoran","year":"2018","journal-title":"Cancer Discov."},{"key":"10.1016\/j.bbrc.2025.152172_bib15","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1016\/S1470-2045(17)30679-4","article-title":"Dabrafenib plus trametinib in patients with previously untreated BRAF(V600E)-mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial","volume":"18","author":"Planchard","year":"2017","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.bbrc.2025.152172_bib16","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1038\/s41391-019-0134-5","article-title":"MEK-ERK signaling is a therapeutic target in metastatic castration resistant prostate cancer","volume":"22","author":"Nickols","year":"2019","journal-title":"Prostate Cancer Prostatic Dis."},{"key":"10.1016\/j.bbrc.2025.152172_bib17","first-page":"29","article-title":"[China guideline for the screening and early detection of prostate cancer (2022, Beijing)]","volume":"44","author":"He","year":"2022","journal-title":"Zhonghua Zhongliu Zazhi"},{"key":"10.1016\/j.bbrc.2025.152172_bib18","doi-asserted-by":"crossref","first-page":"2319","DOI":"10.31557\/APJCP.2024.25.7.2319","article-title":"To establish a nomogram prediction of prostate cancer based on pyroptosis-related genes that affect the immune microenvironment","volume":"25","author":"Ji","year":"2024","journal-title":"Asian Pac. J. Cancer Prev. APJCP"},{"key":"10.1016\/j.bbrc.2025.152172_bib19","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.canlet.2017.05.028","article-title":"Suppression of Akt1-beta-catenin pathway in advanced prostate cancer promotes TGFbeta1-mediated epithelial to mesenchymal transition and metastasis","volume":"402","author":"Gao","year":"2017","journal-title":"Cancer Lett."},{"key":"10.1016\/j.bbrc.2025.152172_bib20","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1002\/mc.20716","article-title":"Fyn is induced by Ras\/PI3K\/Akt signaling and is required for enhanced invasion\/migration","volume":"50","author":"Yadav","year":"2011","journal-title":"Mol. Carcinog."},{"key":"10.1016\/j.bbrc.2025.152172_bib21","doi-asserted-by":"crossref","first-page":"2312","DOI":"10.1038\/sj.bjc.6601814","article-title":"Serum levels of IL-6 and TNF-Alpha correlate with clinicopathological features and patient survival in patients with prostate cancer","volume":"90","author":"Michalaki","year":"2004","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.bbrc.2025.152172_bib22","first-page":"14","article-title":"Genomic landscape alterations in primary tumor and matched lymph node metastasis in hormone-naive prostate cancer patients","author":"Russo","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.bbrc.2025.152172_bib23","doi-asserted-by":"crossref","DOI":"10.1016\/j.mcpro.2023.100613","article-title":"Identifying patients with rapid progression from hormone-sensitive to castration-resistant prostate cancer: a retrospective study","volume":"22","author":"Pan","year":"2023","journal-title":"Mol. Cell. Proteomics"},{"key":"10.1016\/j.bbrc.2025.152172_bib24","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1158\/1535-7163.MCT-20-0244","article-title":"Identification of genes required for enzalutamide resistance in castration-resistant prostate cancer cells in vitro","volume":"20","author":"Kohrt","year":"2021","journal-title":"Mol. Cancer Therapeut."},{"key":"10.1016\/j.bbrc.2025.152172_bib25","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2022.108269","article-title":"The role of mixed lineage kinase 3 (MLK3) in cancers","volume":"238","author":"Ramachandraiah","year":"2022","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.bbrc.2025.152172_bib26","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.semcancer.2021.11.001","article-title":"Understanding and targeting prostate cancer cell heterogeneity and plasticity","volume":"82","author":"Tang","year":"2022","journal-title":"Semin. Cancer Biol."},{"key":"10.1016\/j.bbrc.2025.152172_bib27","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0038950","article-title":"Identification of kinases regulating prostate cancer cell growth using an RNAi phenotypic screen","volume":"7","author":"Whitworth","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.bbrc.2025.152172_bib28","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.1038\/s41388-024-03055-8","article-title":"MLK3 promotes prooncogenic signaling in hepatocellular carcinoma via TGFbeta pathway","volume":"43","author":"Ke","year":"2024","journal-title":"Oncogene"},{"key":"10.1016\/j.bbrc.2025.152172_bib29","first-page":"162","article-title":"Amyloid precursor protein promotes the migration and invasion of breast cancer cells by regulating the MAPK signaling pathway","volume":"45","author":"Wu","year":"2020","journal-title":"Int. J. Mol. Med."},{"key":"10.1016\/j.bbrc.2025.152172_bib30","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1038\/s41423-020-0488-6","article-title":"The history and advances in cancer immunotherapy: understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications","volume":"17","author":"Zhang","year":"2020","journal-title":"Cell. Mol. Immunol."},{"key":"10.1016\/j.bbrc.2025.152172_bib31","article-title":"Immune microenvironment infiltration landscape and immune-related subtypes in prostate cancer","volume":"13","author":"Wu","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.bbrc.2025.152172_bib32","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1038\/s41571-022-00619-z","article-title":"B cells and tertiary lymphoid structures as determinants of tumour immune contexture and clinical outcome","volume":"19","author":"Fridman","year":"2022","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.bbrc.2025.152172_bib33","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1093\/intimm\/dxab071","article-title":"Plasma cell generation during T-cell-dependent immune responses","volume":"33","author":"Ise","year":"2021","journal-title":"Int. Immunol."},{"key":"10.1016\/j.bbrc.2025.152172_bib34","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1038\/s41568-022-00466-1","article-title":"Tumour-infiltrating B cells: immunological mechanisms, clinical impact and therapeutic opportunities","volume":"22","author":"Laumont","year":"2022","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.bbrc.2025.152172_bib35","article-title":"Targeting tumor-infiltrating tregs for improved antitumor responses","volume":"15","author":"Qin","year":"2024","journal-title":"Front. Immunol."},{"key":"10.1016\/j.bbrc.2025.152172_bib36","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/j.immuni.2015.08.006","article-title":"Regulatory T cells in tumor-associated tertiary lymphoid structures suppress anti-tumor T cell responses","volume":"43","author":"Joshi","year":"2015","journal-title":"Immunity (Camb., Mass.)"}],"container-title":["Biochemical and Biophysical Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006291X25008873?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006291X25008873?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T14:54:30Z","timestamp":1762095270000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006291X25008873"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":36,"alternative-id":["S0006291X25008873"],"URL":"https:\/\/doi.org\/10.1016\/j.bbrc.2025.152172","relation":{},"ISSN":["0006-291X"],"issn-type":[{"type":"print","value":"0006-291X"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immunosuppressive MAP3K11 as an independent risk factor for progression-free survival promotes prostate cancer metastasis by regulating epithelial-mesenchymal transition","name":"articletitle","label":"Article Title"},{"value":"Biochemical and Biophysical Research Communications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbrc.2025.152172","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"152172"}}